Schwedhelm · British journal of clinical pharmacology 2008 · randomized placebo-controlled crossover trial · n=20

Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism.

Cited 502 times in the scientific literature.

Level 2 - randomized trial

Individual randomized crossover trial

PubMed 17662090 · doi:10.1111/j.1365-2125.2007.02990.x · record verified 2026-08-29

What was done

In a double-blind, randomized, placebo-controlled crossover trial, 20 healthy volunteers completed six different 1-week dosing regimens of placebo, L-citrulline, and L-arginine. Pharmacokinetic parameters (Cmax, Tmax, Cmin, AUC) of plasma L-arginine were evaluated. Measured pharmacodynamic endpoints included the plasma L-arginine to asymmetric dimethylarginine (ADMA) ratio, urinary nitrate and cyclic guanosine monophosphate (cGMP) excretion rates, and flow-mediated vasodilation (FMD).

What was found

Oral L-citrulline dose-dependently increased plasma L-arginine AUC and Cmax more effectively than oral L-arginine (P < 0.01). The highest dose of L-citrulline (3 g twice daily) increased plasma L-arginine Cmin, increased the L-arginine/ADMA ratio from 186 ± 8 to 278 ± 14 (P < 0.01, 95% CI 66, 121), increased urinary nitrate excretion from 92 ± 10 to 125 ± 15 µmol mmol(-1) creatinine (P = 0.01, 95% CI 8, 58), and increased urinary cGMP excretion from 38 ± 3.3 to 50 ± 6.7 nmol mmol(-1) creatinine (P = 0.04, 95% CI 0.4, 24). No treatment improved FMD over baseline, though pooled analysis showed a correlation between increased arginine/ADMA ratio and FMD improvement.

Why it matters

Oral L-citrulline increases systemic L-arginine concentrations and downstream nitric oxide signaling markers more effectively than direct oral L-arginine administration.

Limits

The trial included a small sample size of only 20 healthy participants with intact baseline endothelial function, limiting generalizability to clinical populations with endothelial dysfunction. Interventions were short (1 week per regimen), and no treatment improved flow-mediated vasodilation over baseline.

Cited by